Medical Care

Global Tumor Immunotherapy Market Research Report 2025

This report aims to provide a comprehensive presentation of the global market for Tumor Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Immunotherapy.
The Tumor Immunotherapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Tumor Immunotherapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumor Immunotherapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Merck
Novartis
Johnson & Johnson
GlaxoSmithKline
AbbVie
ELI Lilly
Amgen
AstraZeneca
Bristol-Mysers Squibb
Kite Pharma
Adaptimmune
Altor Bioscience Corporation
Cellectis
Juno Therapeutics
Takara Bio
Unum Therapeutics
Sunway
Junshi Bio
Cinda Bio
BeiGene
Segment by Type
Tumor Infiltrating Lymphocyte (TIL) Treatment
Engineered T Cell Receptor (TCR) Therapy
Chimeric Antigen Receptor (CAR) T Cell Therapy
Natural Killer (NK) Cell Therapy
Other
Segment by Application
Biopharmaceutical Company
Hospital
Universities And Other Scientific Research Institutions
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tumor Immunotherapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Immunotherapy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Tumor Infiltrating Lymphocyte (TIL) Treatment
1.2.3 Engineered T Cell Receptor (TCR) Therapy
1.2.4 Chimeric Antigen Receptor (CAR) T Cell Therapy
1.2.5 Natural Killer (NK) Cell Therapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Tumor Immunotherapy Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Biopharmaceutical Company
1.3.3 Hospital
1.3.4 Universities And Other Scientific Research Institutions
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor Immunotherapy Market Perspective (2020-2031)
2.2 Global Tumor Immunotherapy Growth Trends by Region
2.2.1 Global Tumor Immunotherapy Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Tumor Immunotherapy Historic Market Size by Region (2020-2025)
2.2.3 Tumor Immunotherapy Forecasted Market Size by Region (2026-2031)
2.3 Tumor Immunotherapy Market Dynamics
2.3.1 Tumor Immunotherapy Industry Trends
2.3.2 Tumor Immunotherapy Market Drivers
2.3.3 Tumor Immunotherapy Market Challenges
2.3.4 Tumor Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor Immunotherapy Players by Revenue
3.1.1 Global Top Tumor Immunotherapy Players by Revenue (2020-2025)
3.1.2 Global Tumor Immunotherapy Revenue Market Share by Players (2020-2025)
3.2 Global Tumor Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Tumor Immunotherapy Revenue
3.4 Global Tumor Immunotherapy Market Concentration Ratio
3.4.1 Global Tumor Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Immunotherapy Revenue in 2024
3.5 Global Key Players of Tumor Immunotherapy Head office and Area Served
3.6 Global Key Players of Tumor Immunotherapy, Product and Application
3.7 Global Key Players of Tumor Immunotherapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor Immunotherapy Breakdown Data by Type
4.1 Global Tumor Immunotherapy Historic Market Size by Type (2020-2025)
4.2 Global Tumor Immunotherapy Forecasted Market Size by Type (2026-2031)
5 Tumor Immunotherapy Breakdown Data by Application
5.1 Global Tumor Immunotherapy Historic Market Size by Application (2020-2025)
5.2 Global Tumor Immunotherapy Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Tumor Immunotherapy Market Size (2020-2031)
6.2 North America Tumor Immunotherapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Tumor Immunotherapy Market Size by Country (2020-2025)
6.4 North America Tumor Immunotherapy Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumor Immunotherapy Market Size (2020-2031)
7.2 Europe Tumor Immunotherapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Tumor Immunotherapy Market Size by Country (2020-2025)
7.4 Europe Tumor Immunotherapy Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tumor Immunotherapy Market Size (2020-2031)
8.2 Asia-Pacific Tumor Immunotherapy Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Tumor Immunotherapy Market Size by Region (2020-2025)
8.4 Asia-Pacific Tumor Immunotherapy Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tumor Immunotherapy Market Size (2020-2031)
9.2 Latin America Tumor Immunotherapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Tumor Immunotherapy Market Size by Country (2020-2025)
9.4 Latin America Tumor Immunotherapy Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor Immunotherapy Market Size (2020-2031)
10.2 Middle East & Africa Tumor Immunotherapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Tumor Immunotherapy Market Size by Country (2020-2025)
10.4 Middle East & Africa Tumor Immunotherapy Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Tumor Immunotherapy Introduction
11.1.4 Roche Revenue in Tumor Immunotherapy Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Tumor Immunotherapy Introduction
11.2.4 Merck Revenue in Tumor Immunotherapy Business (2020-2025)
11.2.5 Merck Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Tumor Immunotherapy Introduction
11.3.4 Novartis Revenue in Tumor Immunotherapy Business (2020-2025)
11.3.5 Novartis Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Tumor Immunotherapy Introduction
11.4.4 Johnson & Johnson Revenue in Tumor Immunotherapy Business (2020-2025)
11.4.5 Johnson & Johnson Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Tumor Immunotherapy Introduction
11.5.4 GlaxoSmithKline Revenue in Tumor Immunotherapy Business (2020-2025)
11.5.5 GlaxoSmithKline Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Details
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Tumor Immunotherapy Introduction
11.6.4 AbbVie Revenue in Tumor Immunotherapy Business (2020-2025)
11.6.5 AbbVie Recent Development
11.7 ELI Lilly
11.7.1 ELI Lilly Company Details
11.7.2 ELI Lilly Business Overview
11.7.3 ELI Lilly Tumor Immunotherapy Introduction
11.7.4 ELI Lilly Revenue in Tumor Immunotherapy Business (2020-2025)
11.7.5 ELI Lilly Recent Development
11.8 Amgen
11.8.1 Amgen Company Details
11.8.2 Amgen Business Overview
11.8.3 Amgen Tumor Immunotherapy Introduction
11.8.4 Amgen Revenue in Tumor Immunotherapy Business (2020-2025)
11.8.5 Amgen Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Details
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Tumor Immunotherapy Introduction
11.9.4 AstraZeneca Revenue in Tumor Immunotherapy Business (2020-2025)
11.9.5 AstraZeneca Recent Development
11.10 Bristol-Mysers Squibb
11.10.1 Bristol-Mysers Squibb Company Details
11.10.2 Bristol-Mysers Squibb Business Overview
11.10.3 Bristol-Mysers Squibb Tumor Immunotherapy Introduction
11.10.4 Bristol-Mysers Squibb Revenue in Tumor Immunotherapy Business (2020-2025)
11.10.5 Bristol-Mysers Squibb Recent Development
11.11 Kite Pharma
11.11.1 Kite Pharma Company Details
11.11.2 Kite Pharma Business Overview
11.11.3 Kite Pharma Tumor Immunotherapy Introduction
11.11.4 Kite Pharma Revenue in Tumor Immunotherapy Business (2020-2025)
11.11.5 Kite Pharma Recent Development
11.12 Adaptimmune
11.12.1 Adaptimmune Company Details
11.12.2 Adaptimmune Business Overview
11.12.3 Adaptimmune Tumor Immunotherapy Introduction
11.12.4 Adaptimmune Revenue in Tumor Immunotherapy Business (2020-2025)
11.12.5 Adaptimmune Recent Development
11.13 Altor Bioscience Corporation
11.13.1 Altor Bioscience Corporation Company Details
11.13.2 Altor Bioscience Corporation Business Overview
11.13.3 Altor Bioscience Corporation Tumor Immunotherapy Introduction
11.13.4 Altor Bioscience Corporation Revenue in Tumor Immunotherapy Business (2020-2025)
11.13.5 Altor Bioscience Corporation Recent Development
11.14 Cellectis
11.14.1 Cellectis Company Details
11.14.2 Cellectis Business Overview
11.14.3 Cellectis Tumor Immunotherapy Introduction
11.14.4 Cellectis Revenue in Tumor Immunotherapy Business (2020-2025)
11.14.5 Cellectis Recent Development
11.15 Juno Therapeutics
11.15.1 Juno Therapeutics Company Details
11.15.2 Juno Therapeutics Business Overview
11.15.3 Juno Therapeutics Tumor Immunotherapy Introduction
11.15.4 Juno Therapeutics Revenue in Tumor Immunotherapy Business (2020-2025)
11.15.5 Juno Therapeutics Recent Development
11.16 Takara Bio
11.16.1 Takara Bio Company Details
11.16.2 Takara Bio Business Overview
11.16.3 Takara Bio Tumor Immunotherapy Introduction
11.16.4 Takara Bio Revenue in Tumor Immunotherapy Business (2020-2025)
11.16.5 Takara Bio Recent Development
11.17 Unum Therapeutics
11.17.1 Unum Therapeutics Company Details
11.17.2 Unum Therapeutics Business Overview
11.17.3 Unum Therapeutics Tumor Immunotherapy Introduction
11.17.4 Unum Therapeutics Revenue in Tumor Immunotherapy Business (2020-2025)
11.17.5 Unum Therapeutics Recent Development
11.18 Sunway
11.18.1 Sunway Company Details
11.18.2 Sunway Business Overview
11.18.3 Sunway Tumor Immunotherapy Introduction
11.18.4 Sunway Revenue in Tumor Immunotherapy Business (2020-2025)
11.18.5 Sunway Recent Development
11.19 Junshi Bio
11.19.1 Junshi Bio Company Details
11.19.2 Junshi Bio Business Overview
11.19.3 Junshi Bio Tumor Immunotherapy Introduction
11.19.4 Junshi Bio Revenue in Tumor Immunotherapy Business (2020-2025)
11.19.5 Junshi Bio Recent Development
11.20 Cinda Bio
11.20.1 Cinda Bio Company Details
11.20.2 Cinda Bio Business Overview
11.20.3 Cinda Bio Tumor Immunotherapy Introduction
11.20.4 Cinda Bio Revenue in Tumor Immunotherapy Business (2020-2025)
11.20.5 Cinda Bio Recent Development
11.21 BeiGene
11.21.1 BeiGene Company Details
11.21.2 BeiGene Business Overview
11.21.3 BeiGene Tumor Immunotherapy Introduction
11.21.4 BeiGene Revenue in Tumor Immunotherapy Business (2020-2025)
11.21.5 BeiGene Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Tumor Immunotherapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Tumor Infiltrating Lymphocyte (TIL) Treatment
Table 3. Key Players of Engineered T Cell Receptor (TCR) Therapy
Table 4. Key Players of Chimeric Antigen Receptor (CAR) T Cell Therapy
Table 5. Key Players of Natural Killer (NK) Cell Therapy
Table 6. Key Players of Other
Table 7. Global Tumor Immunotherapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Tumor Immunotherapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Tumor Immunotherapy Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Tumor Immunotherapy Market Share by Region (2020-2025)
Table 11. Global Tumor Immunotherapy Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Tumor Immunotherapy Market Share by Region (2026-2031)
Table 13. Tumor Immunotherapy Market Trends
Table 14. Tumor Immunotherapy Market Drivers
Table 15. Tumor Immunotherapy Market Challenges
Table 16. Tumor Immunotherapy Market Restraints
Table 17. Global Tumor Immunotherapy Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Tumor Immunotherapy Market Share by Players (2020-2025)
Table 19. Global Top Tumor Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunotherapy as of 2024)
Table 20. Ranking of Global Top Tumor Immunotherapy Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Tumor Immunotherapy Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Tumor Immunotherapy, Headquarters and Area Served
Table 23. Global Key Players of Tumor Immunotherapy, Product and Application
Table 24. Global Key Players of Tumor Immunotherapy, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Tumor Immunotherapy Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Tumor Immunotherapy Revenue Market Share by Type (2020-2025)
Table 28. Global Tumor Immunotherapy Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Tumor Immunotherapy Revenue Market Share by Type (2026-2031)
Table 30. Global Tumor Immunotherapy Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Tumor Immunotherapy Revenue Market Share by Application (2020-2025)
Table 32. Global Tumor Immunotherapy Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Tumor Immunotherapy Revenue Market Share by Application (2026-2031)
Table 34. North America Tumor Immunotherapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Tumor Immunotherapy Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Tumor Immunotherapy Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Tumor Immunotherapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Tumor Immunotherapy Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Tumor Immunotherapy Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Tumor Immunotherapy Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Tumor Immunotherapy Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Tumor Immunotherapy Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Tumor Immunotherapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Tumor Immunotherapy Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Tumor Immunotherapy Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Tumor Immunotherapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Tumor Immunotherapy Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Tumor Immunotherapy Market Size by Country (2026-2031) & (US$ Million)
Table 49. Roche Company Details
Table 50. Roche Business Overview
Table 51. Roche Tumor Immunotherapy Product
Table 52. Roche Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 53. Roche Recent Development
Table 54. Merck Company Details
Table 55. Merck Business Overview
Table 56. Merck Tumor Immunotherapy Product
Table 57. Merck Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 58. Merck Recent Development
Table 59. Novartis Company Details
Table 60. Novartis Business Overview
Table 61. Novartis Tumor Immunotherapy Product
Table 62. Novartis Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 63. Novartis Recent Development
Table 64. Johnson & Johnson Company Details
Table 65. Johnson & Johnson Business Overview
Table 66. Johnson & Johnson Tumor Immunotherapy Product
Table 67. Johnson & Johnson Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 68. Johnson & Johnson Recent Development
Table 69. GlaxoSmithKline Company Details
Table 70. GlaxoSmithKline Business Overview
Table 71. GlaxoSmithKline Tumor Immunotherapy Product
Table 72. GlaxoSmithKline Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 73. GlaxoSmithKline Recent Development
Table 74. AbbVie Company Details
Table 75. AbbVie Business Overview
Table 76. AbbVie Tumor Immunotherapy Product
Table 77. AbbVie Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 78. AbbVie Recent Development
Table 79. ELI Lilly Company Details
Table 80. ELI Lilly Business Overview
Table 81. ELI Lilly Tumor Immunotherapy Product
Table 82. ELI Lilly Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 83. ELI Lilly Recent Development
Table 84. Amgen Company Details
Table 85. Amgen Business Overview
Table 86. Amgen Tumor Immunotherapy Product
Table 87. Amgen Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 88. Amgen Recent Development
Table 89. AstraZeneca Company Details
Table 90. AstraZeneca Business Overview
Table 91. AstraZeneca Tumor Immunotherapy Product
Table 92. AstraZeneca Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 93. AstraZeneca Recent Development
Table 94. Bristol-Mysers Squibb Company Details
Table 95. Bristol-Mysers Squibb Business Overview
Table 96. Bristol-Mysers Squibb Tumor Immunotherapy Product
Table 97. Bristol-Mysers Squibb Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 98. Bristol-Mysers Squibb Recent Development
Table 99. Kite Pharma Company Details
Table 100. Kite Pharma Business Overview
Table 101. Kite Pharma Tumor Immunotherapy Product
Table 102. Kite Pharma Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 103. Kite Pharma Recent Development
Table 104. Adaptimmune Company Details
Table 105. Adaptimmune Business Overview
Table 106. Adaptimmune Tumor Immunotherapy Product
Table 107. Adaptimmune Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 108. Adaptimmune Recent Development
Table 109. Altor Bioscience Corporation Company Details
Table 110. Altor Bioscience Corporation Business Overview
Table 111. Altor Bioscience Corporation Tumor Immunotherapy Product
Table 112. Altor Bioscience Corporation Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 113. Altor Bioscience Corporation Recent Development
Table 114. Cellectis Company Details
Table 115. Cellectis Business Overview
Table 116. Cellectis Tumor Immunotherapy Product
Table 117. Cellectis Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 118. Cellectis Recent Development
Table 119. Juno Therapeutics Company Details
Table 120. Juno Therapeutics Business Overview
Table 121. Juno Therapeutics Tumor Immunotherapy Product
Table 122. Juno Therapeutics Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 123. Juno Therapeutics Recent Development
Table 124. Takara Bio Company Details
Table 125. Takara Bio Business Overview
Table 126. Takara Bio Tumor Immunotherapy Product
Table 127. Takara Bio Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 128. Takara Bio Recent Development
Table 129. Unum Therapeutics Company Details
Table 130. Unum Therapeutics Business Overview
Table 131. Unum Therapeutics Tumor Immunotherapy Product
Table 132. Unum Therapeutics Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 133. Unum Therapeutics Recent Development
Table 134. Sunway Company Details
Table 135. Sunway Business Overview
Table 136. Sunway Tumor Immunotherapy Product
Table 137. Sunway Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 138. Sunway Recent Development
Table 139. Junshi Bio Company Details
Table 140. Junshi Bio Business Overview
Table 141. Junshi Bio Tumor Immunotherapy Product
Table 142. Junshi Bio Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 143. Junshi Bio Recent Development
Table 144. Cinda Bio Company Details
Table 145. Cinda Bio Business Overview
Table 146. Cinda Bio Tumor Immunotherapy Product
Table 147. Cinda Bio Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 148. Cinda Bio Recent Development
Table 149. BeiGene Company Details
Table 150. BeiGene Business Overview
Table 151. BeiGene Tumor Immunotherapy Product
Table 152. BeiGene Revenue in Tumor Immunotherapy Business (2020-2025) & (US$ Million)
Table 153. BeiGene Recent Development
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
Table 157. Authors List of This Report


List of Figures
Figure 1. Tumor Immunotherapy Picture
Figure 2. Global Tumor Immunotherapy Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Tumor Immunotherapy Market Share by Type: 2024 VS 2031
Figure 4. Tumor Infiltrating Lymphocyte (TIL) Treatment Features
Figure 5. Engineered T Cell Receptor (TCR) Therapy Features
Figure 6. Chimeric Antigen Receptor (CAR) T Cell Therapy Features
Figure 7. Natural Killer (NK) Cell Therapy Features
Figure 8. Other Features
Figure 9. Global Tumor Immunotherapy Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Tumor Immunotherapy Market Share by Application: 2024 VS 2031
Figure 11. Biopharmaceutical Company Case Studies
Figure 12. Hospital Case Studies
Figure 13. Universities And Other Scientific Research Institutions Case Studies
Figure 14. Other Case Studies
Figure 15. Tumor Immunotherapy Report Years Considered
Figure 16. Global Tumor Immunotherapy Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Tumor Immunotherapy Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Tumor Immunotherapy Market Share by Region: 2024 VS 2031
Figure 19. Global Tumor Immunotherapy Market Share by Players in 2024
Figure 20. Global Top Tumor Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunotherapy as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by Tumor Immunotherapy Revenue in 2024
Figure 22. North America Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Tumor Immunotherapy Market Share by Country (2020-2031)
Figure 24. United States Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Tumor Immunotherapy Market Share by Country (2020-2031)
Figure 28. Germany Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Tumor Immunotherapy Market Share by Region (2020-2031)
Figure 36. China Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Tumor Immunotherapy Market Share by Country (2020-2031)
Figure 44. Mexico Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Tumor Immunotherapy Market Share by Country (2020-2031)
Figure 48. Turkey Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Tumor Immunotherapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Roche Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 52. Merck Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 53. Novartis Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 54. Johnson & Johnson Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 55. GlaxoSmithKline Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 56. AbbVie Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 57. ELI Lilly Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 58. Amgen Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 59. AstraZeneca Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 60. Bristol-Mysers Squibb Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 61. Kite Pharma Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 62. Adaptimmune Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 63. Altor Bioscience Corporation Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 64. Cellectis Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 65. Juno Therapeutics Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 66. Takara Bio Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 67. Unum Therapeutics Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 68. Sunway Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 69. Junshi Bio Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 70. Cinda Bio Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 71. BeiGene Revenue Growth Rate in Tumor Immunotherapy Business (2020-2025)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies